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http://www.trialsjournal.com/content/14/1/83STUDY PROTOCOL Open AccessStudy of Optimal Replacement of Thyroxine in
the ElDerly (SORTED): protocol for a mixed
methods feasibility study to assess the clinical
utility of lower dose thyroxine in elderly
hypothyroid patients: study protocol for a
randomized controlled trial
Scott Wilkes1, Simon Pearce2, Vicky Ryan1, Tim Rapley1, Lorna Ingoe3 and Salman Razvi2,3*Abstract
Background: The population of the UK is ageing. There is compelling evidence that thyroid stimulating hormone
distribution levels increase with age. Currently, in UK clinical practice elderly hypothyroid patients are treated with
levothyroxine to lower their thyroid stimulating hormone levels to a standard non-age-related range. Evidence
suggests that mortality is negatively associated with thyroid stimulating hormone levels. We report the protocol of
a feasibility study working towards a full-scale randomized controlled trial to test whether lower dose levothyroxine
has beneficial cardiovascular outcomes in the oldest old.
Methods/design: SORTED is a mixed methods study with three components:
SORTED A: A feasibility study of a dual-center single-blinded randomized controlled trial of elderly hypothyroid
patients currently treated with levothyroxine.
Setting: Patients will be recruited from 20 general practices and two hospital trust endocrine units in
Northumberland, Tyne and Wear.
Participants: Target recruitment of 50 elderly hypothyroid patients currently treated with levothyroxine, identified in
both primary and secondary care settings.
Intervention: Reduced dose of levothyroxine to achieve an elevated serum thyroid stimulating hormone (target
range 4.1 to 8.0 mU/L) versus standard levothyroxine replacement (target range 0.4 to 4.0 mU/L).
Randomization: Using random permuted blocks, in a ratio of 1:1, randomization will be carried out by Newcastle
Clinical Trials Unit.
Outcomes: Study feasibility (recruitment and retention rates and medication compliance), acceptability of the trial
design, assessment of mobility and falls risk, and change in cardiovascular risk factors.
SORTED B: Qualitative study using in-depth interviews to understand patients’ willingness to take part in a
randomized controlled trial and participants’ experience of the intervention.
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SORTED C: Retrospective cohort study of 400 treated hypothyroid patients aged 80 years or over registered in 2008
in primary care practices, studying their 4-year cardiovascular outcomes to inform the power of SORTED II.
Discussion: This is a study to evaluate the feasibility of conducting a randomized controlled trial in elderly
hypothyroid patients in general practice and hospital settings. The results will inform the design of the definitive
SORTED II trial to evaluate the effects of lower dose thyroxine in elderly hypothyroid patients.
Trial registration: Current Controlled Trials ISRCTN16043724
Keywords: Hypothyroidism, Ageing, General practice, Primary health care, Cardiovascular disease, Thyroxine,
Feasibility, Randomized controlled trialBackground
The population of the UK is ageing. Over the last 25 years
the percentage of the population aged 65 and over
increased from 15% in 1984 to 16% in 2009, an increase of
1.7 million people. Over the same period, the percentage
of the population aged under 16 decreased from 21% to
19%. This trend is projected to continue. By 2034, 23% of
the population is projected to be aged 65 and over com-
pared to 18% aged under 16.
The greatest population increase has been in the num-
ber of those aged 85 and over, the ‘oldest old’. In 1984,
there were around 660,000 people in the UK aged 85 and
over. Since then the numbers have more than doubled
reaching 1.4 million in 2009. By 2034 the number of
people aged 85 and over is projected to be 2.5 times larger
than in 2009, reaching 3.5 million and accounting for 5%
of the total population [1].
Thyroid hormones are crucial in controlling metabolism
and have an impact on a wide array of tissues including
brain, heart, muscle and bones. Thyroid dysfunction is
common, affecting all age groups, with a higher frequency
in women and older individuals. In the NHANES III
survey, a study designed to provide normative estimates of
health and nutritional parameters in the USA, a raised serum
thyroid stimulating hormone (TSH) level (>4.5 mU/L) was
found in 14% of the population aged 80 years or over
[2]. In the UK, the population-based Whickham study
found that 10% of the population over the age of 75 years
had a raised TSH level (>6.0 mU/L) [3]. There is compel-
ling evidence that serum TSH distribution levels increase
progressively with age in the reference population with
the 97.5th centile being 4.03 mU/L in the 50 to 59 age
group and 7.49 mU/L in the 80+ age group [4]. There-
fore the prevalence of hypothyroidism and subclinical
hypothyroidism is likely to be significantly overestimated
in the oldest old and, more importantly, treatment with
levothyroxine (LT4) inappropriately initiated in a propor-
tion of these.
Treating elderly patients who have mildly elevated TSH
with LT4 does not improve cognitive function [5]. It is
recognized that over-treatment with thyroid hormones
has the potential for deleterious effects on quality of life,skeletal health, cardiovascular mortality and incidence of
atrial fibrillation [6]. This finding has been borne out in
the well-designed prospective follow-up study of 85-year
-old individuals in Leiden [7]. This study showed that
mortality was negatively associated with TSH levels and
increased with higher free thyroxine levels. Furthermore,
in the same study, subgroup analyses after exclusion of
individuals on medication for thyroid disease showed that
higher TSH and lower thyroxine levels were associated
with reduced worsening of disability, better memory and
reduced mortality over 4 years of follow-up. In another
study of older untreated adults aged more than 70 years, a
mildly elevated TSH between 4.5 and 7.0 mU/L was asso-
ciated with a slight functional advantage in mobility com-
pared to those with TSH levels of 0.4 to 4.5 mU/L [8].
This suggests that treatment with thyroid hormones could
worsen these important outcomes in elderly individuals.
Another study of older women (>65 years) found that
mortality in thyroid hormone users tended to be higher
with a hazard ratio (95% CI) of 1.11 (0.98 to 1.24) and that
mildly elevated TSH was not associated with excess car-
diovascular mortality [9]. A meta-analysis of observational
population-based studies [10], and confirmed by others
[11], has shown that mild hypothyroidism in the elderly is
not hazardous for vascular mortality and events.
Currently, all individuals with hypothyroidism are treated
as a homogenous group irrespective of age with the aim of
achieving serum TSH levels within the reference range (0.4
to 4.0 mU/L). However, thyroxine metabolism is altered in
advanced age, and ‘age-adjusted’ reference ranges are not
employed [12]. Experts suggest that in older hypothyroid
patients LT4 treatment should be tailored to have a higher
‘target’ TSH value compared to younger individuals and
that ‘prospective therapeutic trials are necessary to clarify
the necessity of replacement therapy in the elderly’ [6].
There is neither consensus nor published NICE clinical
guidelines to help clinicians manage mild hypothyroidism
or subclinical hypothyroidism in older patients. This pre-
sents a significant problem for general practitioners (GPs),
who manage the majority of these patients [13]. It is im-
perative to gather evidence and determine whether they
should be treated with a more appropriate TSH target, and
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morbidity and mortality.
The future definitive trial: SORTED II
The objective of SORTED II is to address the question of
whether elderly hypothyroid patients maintained with a
slightly higher TSH reference range, have better morbidity,
mortality and cardiovascular outcomes, compared with
current usual treatment. Where the feasibility, patient
acceptability and parameters to inform a power calculation
are lacking for a definitive trial, a well-designed feasibility
study is required [14]. In the SORTED study we will test
protocol procedures, patient recruitment and retention
rates, consent processes, randomization, patient accept-
ability, and collect data to power SORTED II. This
paper describes the three components of the protocol
for the feasibility study SORTED, a necessary precursor
to SORTED II.
Methods/design
Aim: SORTED (A, B and C)
The aim of this study is to explore the design, patient
acceptability and required sample size to power the de-
finitive SORTED II trial adequately. Specifically we aim
to provide evidence that it is feasible to perform a large
randomized controlled trial (RCT) assessing lower dose
LT4 in treated elderly hypothyroid patients, evaluating
the participants’ experience in the trial as well as
morbidity and mortality rates over 4 years in a cohort of
patients in general practice.
SORTED A: RCT feasibility study
Aim
The aim is to assess participants’ willingness to enter and
complete a single-blinded randomized controlled trial of
lower dose thyroxine for elderly hypothyroid patients.
Primary objectives
The primary objectives are to show that recruitment to
such a trial is possible; to gauge participants’ acceptabil-
ity of being part of the study; to assess the length of time
required to complete recruitment; to assess the dose
titration strategy and the length of time required to
achieve desired TSH levels; and to gauge medication
compliance.
Secondary objectives
The secondary objectives are to measure the acceptability
and usefulness of generic and validated disease-specific
quality of life questionnaires, EQ-5D [15], ThyDQoL and
ThySRQ [16]; to assess mobility and risk of falls in this
population group as measured by the TUG test and FRAT
questionnaire [17]; and to measure changes in specific
cardiovascular risk factors including lipid profile, bloodpressure and body weight and changes in bone resorption
markers.
Design
This is a feasibility study for a dual-center single-blinded
RCT of elderly hypothyroid patients currently treated
with LT4. It is a clinical trial of an investigational medi-
cinal product. The study will compare the standard dose
of LT4 (target TSH level 0.4 to 4.0 mU/L) with a lower
dose of LT4 (target TSH levels 4.1 to 8.0 mU/L), until
TSH is within the desired range. Post randomization,
individuals will be assessed at 12 weeks (and LT4 dose
adjusted) and at 24 weeks, with a final follow-up phone
call at 25 weeks.
Study setting and population
Patients will be recruited from 20 research general prac-
tices that are supported by the National Institute for
Health Research (NIHR), and two hospital trust endo-
crine units in Northumberland, Tyne and Wear. The
study population comprises elderly hypothyroid patients
currently treated with LT4.
Inclusion criteria
Males and females aged 80 years or over are included if:
 They have been diagnosed with hypothyroidism and
treated with LT4 for at least 6 months.
 They are living independently in the community.
 All of their TSH results are within the range 0.4 to
4 mU/L in the 3 months before commencing the
study.
 They have provided written informed consent for
participation in the study, prior to any study-specific
procedures.
Exclusion criteria
People are excluded if:
 They have established dementia and therefore
deemed incapable of providing informed consent.
 They have other medical conditions, which, in the
opinion of the chief investigator, would prevent
them from taking part in the study (for example,
end stage cancer or severe chronic health conditions
where the patient is housebound).
 They are a resident of a nursing home or residential
care home.
 They have with thyroid cancer, as they would
require high doses of LT4 to suppress their serum
TSH.
 They take 25 mcg of LT4 daily: dose reduction will
mean that they stop thyroid replacement treatment.
 They do not speak English.
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trials within the last 3 months.
 They have been prescribed medications that can
affect thyroid function (amiodarone, lithium,
carbimazole or propylthiouracil).
 They have known or suspected lactose intolerance
(this would have implications for the proposed
over-encapsulated investigational medicinal product
(IMP)).
Screening, recruitment and consent
Three methods of recruitment will be adopted for the
RCT feasibility study: via a database search of GP prac-
tices, opportunistically via secondary care clinics and via
poster advertising and self-referral.All patients dead or alive and ≥ 80 y
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be identified and invited to participate during routine
endocrine clinic visits at the Gateshead Health NHS
Foundation Trust and the Newcastle upon Tyne Hospitals
NHS Foundation Trust. The initial approach in the clinic
will be via the clinician in charge of their routine clinical
care. A brief verbal explanation of the study will be pro-
vided by the clinician and the participant will be given a
study invitation pack.
Finally, we will use study posters in non-research
active practices in and around the Northumberland and
Tyne and Wear area. Potential participants can contact
the central study team directly. The central study team
will assess the eligibility criteria then send a study invita-
tion pack.
Potential participants will receive a study invitation
pack consisting of:
 Either a pre-prepared invitation letter from the
general practice, an invitation letter from their
routine clinician in secondary care, or an invitation
letter from the central study team in response to a
poster enquiry.
 A participant information sheet and consent form.
 A stamped addressed envelope to return the reply
slip to the central study team.
On receipt of the reply slip, the central study team will
contact potential participants by telephone 7 (+/− 3)
days later to confirm the patient’s interest in participat-
ing, answer any initial questions and arrange a conveni-
ent date and time for the screening visit. If potential
participants are not contactable by telephone, then a
home visit appointment will be arranged by letter to dis-
cuss this information.
If no reply slip is received by the central study team
within 4 weeks, a reminder will be sent to the patient’s
home address within 2 working days. The reminder will
also contain an invitation pack for SORTED B Group 2
(see below) to minimize the number of approaches to
each particular patient.
For all potential participants, a screening visit will be
arranged either at the patient’s home, the Clinical
Research Facility, Leazes Wing, Royal Victoria Infirmary
(RVI) or at Bensham Hospital, Gateshead. The central
study team (for those patients reviewed at Bensham
Hospital or at home) or site-specific research staff (for
those patients reviewed at the Clinical Research Facility,
RVI) will discuss the study in detail with the patient and
answer any queries he/she may have. If the patient
wishes to take part in the study, written informed
consent will be obtained at this visit.
The eligibility assessments must occur within 3 months
prior to the baseline visit and the start of participationin the study. Screening logs will be held securely at the
PICs and investigator sites. The screening logs will docu-
ment details of patients invited to participate in the
study.
Intervention
Lower dose LT4 achieving a target TSH level of 4.1 to
8.0 mU/L
Control
Standard dose LT4 achieving a target TSH level of 0.4 to
4.0 mU/L
Randomization
Participants will be randomized to either the usual (current)
dose of LT4 (control) or the lower dose of LT4 (interven-
tion), in a ratio of 1:1, using random permuted blocks.
Randomization will be stratified by usual (pre-study) LT4
dose (50, 75, 100 and 125 mcg daily). Randomization will
be administered centrally via Newcastle Clinical Trials Unit
using a secure password-protected web-based system.
Blinding
Patients will be blind to treatment allocation. The clini-
cians will be aware of the LT4 dose so that they can
maintain treatment within the specified TSH ranges,
either for the usual dose of LT4 (control) or the lower
dose of LT4 (intervention), that is, the trial will be single
blinded. The research team will be aware of the dose
each participant will receive; however, data analysis will
be blinded.
At the final visit, the integrity of the blinding will be
assessed by asking the participants if they thought they
were taking their usual or a lower dose of LT4.
Study medication
The LT4 medication, the IMP, will be used within the
licensed indications [18] in this study. Nonetheless, since
an alternative dosing regime will be tested, additional in-
formation is being gathered on safety and efficacy. As
manufacture will involve de-blistering/over-encapsula-
tion, the study drug will be treated as an IMP for the
purpose of this study, and will be labeled and handled
accordingly.
The study drug will be sourced, assembled and pack-
aged by Newcastle Specials (Pharmacy Production Unit)
at the Newcastle upon Tyne Hospitals NHS Foundation
Trust, MIA(IMP) 17136. The brand of LT4 to be used in
this study will be Eltroxin 25 mcg tablets and Eltroxin
50 mcg tablets (Mercury Pharmaceutical Ltd). This will
be purchased in blister packs.
The single blind will be achieved by de-blistering and
over-encapsulation, using a capsule filler of lactose BP.
For doses that are multiples of 50 mcg, we will over-
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25 mcg, 75 mcg and 125 mcg dose increments, we will
over-encapsulate Eltroxin 25 mcg tablets. This ensures
the capsules are kept as small as possible for ease of
swallowing (DB capsules size A, color: Swedish orange;
manufacturer: Capsugel). Capsules will be repackaged
into a bottle container (polypropylene) and labeled
appropriately.
As it is not feasible to predict in advance exactly how
much IMP must be packaged per study dose, predictions
will be based on known current doses as per routine
clinical practice; production run(s) will generate surplus
stock per IMP dose.
The LT4 medication (Eltroxin 25 mcg and 50 mcg)
will have a maximum shelf-life of 24 months (less any
reduction in expiry due to the shortest expiry date of the
blister packs purchased). The IMP will not be stored
above 25 °C and will be stored in the original container
to protect it from light and moisture, as per the clinical
trial label. A temperature log will be maintained as per
local pharmacy procedures, and appropriate IMP storage
will be guaranteed until the IMP arrives in the patient’s
possession.
The side-effect profile of Eltroxin (25 mcg and 50
mcg) is well known and documented [18]. The total
daily dose provided to each participant will be between
25 mcg and 150 mcg.
Administration of study medication
Participants randomized to the lower dose of LT4 (inter-
vention) to achieve the desired target TSH level of 4.1 to
8.0 mU/L, are likely to have their LT4 medication reduced
by 25 mcg once a day at visit 1.
LT4 will be provided as two separate 13-week supplies
(dispensed separately at visits 1 and 2; see Table 1). The
container will be labeled appropriately but will not indicate
the arm of the study to which the participants have been
randomized. The label will instead contain a pack number,
which will be the link to the relevant packaged dose.
The study medication will be prescribed by an autho-
rized study physician according to the protocol, using a
trial specific prescription (documenting the required
IMP dose), and dispensed according to local pharmacy
practice. The relevant pharmacy will hold a correspond-
ing list allowing pharmacy staff to correlate IMP pack
number with the relevant packaged IMP dose for any
particular IMP bottle, thus maintaining the single blind.
To further maintain the single blind, the research team
at each site will deliver the trial prescription to the phar-
macy and collect the relevant study medication to pro-
vide to the patient. Participants will be advised to take
the IMP capsule orally once a day as usual. This will be
discussed at the time of consent and will be clear in the
patient information sheet.Participants will be informed of potential adverse reac-
tions and advised to contact the relevant study team as
required. A study-specific participant contact card will
also be provided.
Once randomized, participants will begin their study
medication on Day 0 (Table 1).
At 12 weeks (+/− 7 days), serum TSH levels will be
checked and the LT4 dose adjusted as follows (the
second bottle of IMP should be started at week 12 (+/−
7 days)):
Control (usual) dose arm, TSH level:
≤0.39 mU/L: LT4 reduced by 25 mcg once daily
0.4 to 4.0 mU/L: Stay on current dose of LT4
≥4.1 mU/L: LT4 increased by 25 mcg once daily
Lower dose arm, TSH level:
<0.4 to 4.0 mU/L: LT4 reduced by 25 mcg once daily
4.1 to 8.0 mU/L: Stay on current dose of LT4
>8.1 mU/L: LT4 increased by 25 mcg once daily
The LT4 treatment based on the above regimen will
continue for a total of 24 weeks at which point the final
set of study-specific assessments will be made (with a
further follow-up phone call at 25 weeks). If, during the
course of the study, individuals on 25 mcg/day of LT4
require a reduction in their dose of LT4, their LT4 dose
will remain unchanged as otherwise they would need to
discontinue LT4 therapy completely.
At visit 3, participants on each arm of the study will
stop their IMP and will be referred back to their GP,
who will promptly prescribe the LT4 dose they were
taking prior to study participation. The GP letter (sent
once the participant is randomized) and the GP follow-
up letter (sent after each participant completes his/her
IMP) instruct the GP to check TSH levels for each par-
ticipant, three months after he/she has completed his/
her IMP.
At the end of visits 2 and 3, participants will be asked
to return any surplus study drug in the original pack-
aging to the study team, who will verify and document
compliance. All unused study medication and packaging
will be sent to the local pharmacy for documentation
and destruction as per local policy (following appropri-
ate reconciliation by the trial manager).
Documentation of prescribing, dispensing and return of
study medication will be maintained for study records.
Primary outcome measures
 Participants’ willingness to enter the trial (ratio
between those who consented to participate and
those who were eligible and approached)
Table 1 SORTED A study assessments
Pre-screening Screening Baseline Follow-up
Visit 1 2 3 4
(phone call only)
Assessmentsa Within 3 months of
baseline visit
Week −4
to −1
Day 0 Week 12
(+/− 7 days)
Week 24
(+/− 7 days)
Week 25
(+/− 3 days)
Identification and initial approach
(including provision of PIS)
X
Eligibility criteria checked
(as per routine clinical practice)
X
Written informed consent
(including discussion of study in detail, questions
answered)
X
Physical examination
(height,e weight, blood pressure, pulse)
X X
Venepuncture Xb Xc Xd
Clinical history
(relevant medical history, medication list/history)
X
Participant-completed questionnaires
(ThyDQoL, ThySRQ, EQ-5D)
X X
Nurse-administered questionnaires (FRAT, TUG) X X
Randomization (after all eligibility criteria checked
and written informed consent obtained)
X
Study medication prescribed and dispensed
(following LT4 dose assessment at visit 2 only)
X X
Study medication compliance checks X X
Concomitant medication X X X
Adverse events X X
Serious adverse events X X X
a Study-specific procedures must only be performed once written informed consent is obtained from the participant; b 10 ml blood: TSH, FT4, FT3, thyroid
peroxidase antibodies, total cholesterol, HDL, triglycerides, serum CTX; c 5 ml blood: TSH, FT4, FT3 only; d 10 ml blood: TSH, FT4, FT3, total cholesterol, HDL,
triglycerides, serum CTX; e height to be measured at the baseline visit only.
FT3: free triiodothyronine (thyroid hormone); FT4: free thyroxine; HDL: high-density lipoprotein; serum CTX: serum collagen type-1 cross-linked C-telopeptide; TSH:
thyroid stimulating hormone, PIS: participant information sheet.
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measured by the completion rate of participants in
each randomized group).
 Participant recruitment rate (as measured by the
number of patients randomized divided by the
length of the recruitment period) – the recruitment
period runs from the date that recruitment opened
to the date of the last randomization.
 Dose titration strategy, described above, and length
of time required to achieve desired TSH levels
(number of participants in each group that reach
target TSH range at both 12 and 24 weeks)
 Medication compliance (tablet count).
Secondary outcome measures
 Acceptability and usefulness of three patient-
completed questionnaires: a generic quality of life
(QoL) questionnaire (EQ-5D), a validated disease-
specific QoL questionnaire (ThyDQoL) and thedisease-specific hypothyroid symptom checklist
(ThySRQ). The time taken to complete the three
questionnaires will be recorded and questionnaire
completion rates will be calculated. Any third-party
help used in a questionnaire’s completion will be
recorded.
 Assessment of mobility and risk of falls in this
population group as measured by the nurse-
administered TUG and FRAT.
 Changes in specific cardiovascular risk factors (lipid
profile (total cholesterol, high-density lipoprotein,
triglycerides), blood pressure and body weight) and
serum collagen type-1 cross-linked C-telopeptide
(serum CTX).Data collection and outcome assessments
The following procedures and assessments will be car-
ried out in accordance with the study schedule shown in
Table 1.
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 Randomization: Usual or reduced dose of LT4
 Participant-completed questionnaires: ThyDQoL,
ThySRQ and EQ-5D. A private area will be provided
for the participant to complete the questionnaires. If
patients refuse to answer certain questions, their
wishes will be respected. A record of start and finish
times will be retained for patient-completed
questionnaires.
 Nurse-administered questionnaires: FRAT and TUG
 Physical examination: Height, weight, blood
pressure, pulse.
 Venepuncture: 5 to 10 mL blood (TSH, free
thyroxine (FT4), free triiodothyronine (FT3), thyroid
peroxidase antibodies, total cholesterol, high-density
lipoprotein, triglycerides, CTX
 Clinical history: relevant medical history and
medication list.
 Study medication dosing according to dose titration
guidelines.
 Study medication compliance and concomitant
medication checks.
 Clinical history: adverse events, serious adverse
events, changes to concomitant medication.
 Assess integrity of the blind by asking the
participant: ‘It is important for the interpretation of
the results of the study that we ask you the
following: “Do you think you were taking your usual
or a lower dose of LT4? Why do you think this?”’
Data handling and record keeping
Medical information obtained at each visit will be
recorded in the subject’s medical notes or other source
documentation in real time. Data will be collected on
paper case report forms and entered by an authorized
member of the research study team on a secure
validated clinical data management system. Data will be
entered either at Bensham Hospital (for visits conducted
at Bensham or at the participant’s home address) or at
the Clinical Research Facility (for visits conducted at the
RVI). The clinical data management system will be web-
based, allowing access for authorized staff at Newcastle
upon Tyne Hospitals NHS Foundation Trust, Gateshead
Health NHS Foundation Trust and Newcastle University
via password protection. Data will be handled, comput-
erized and stored in accordance with the Data Protec-
tion Act 1998. No participant-identifiable data will leave
the study site (the case report forms will identify partici-
pants by initials, date of birth and unique patient num-
ber only). Strict confidentiality will be ensured while
dealing with patient-sensitive data in accordance with
the Caldicott Guardian’s recommendations (applications
will be made to the relevant Caldicott Guardian for use
of NHS patient data).All study data will be held in strict confidence by the
investigators and research team. Data and documents
will be stored in locked cupboards. A confidential list of
trial identifiers and corresponding patient-identifying de-
tails will be held at site in a locked cupboard by the
principal investigator. The quality and retention of study
data will be the responsibility of the chief investigator.
All study data will be retained in accordance with the
latest Directive on Good Clinical Practice (2005/28/EC)
and local policy.
Submission of accrual data to the UK Clinical Research
Network
This study will apply for adoption to the NIHR Primary
Care Research Network Portfolio. Accrual data will be
submitted on a monthly basis, by Newcastle Clinical Trials
Unit, in accordance with NIHR Clinical Research Network
guidelines.
Study compliance and withdrawal
Compliance with study medication (IMP) will be assessed
and documented by the research team by checking and re-
cording the number of return capsules at each visit. This
allows any issues to be addressed immediately with the
participant. Compliance will be classed as good if between
80% and 100%.
Participants may withdraw from the study at any time
without giving a reason. The investigator may also with-
draw patients from the study drug in the event of inter-
current illness, adverse events, serious adverse events,
suspected unexpected serious adverse reactions, protocol
violations or administrative or other reasons. Partici-
pants who withdraw will be asked if they would be will-
ing to provide follow-up data collected as per the study
protocol. Participants withdrawn from the study will not
be replaced.
Pharmacovigilance
The safety of the lower dose of LT4 in this study will be
evaluated by examining the occurrences of all adverse
events, adverse drug reactions, unexpected adverse reac-
tions, serious adverse reactions or suspected unexpected
serious adverse reactions as defined by the Medicines for
Human Use (Clinical Trials) Regulations [19]. The rela-
tionship and expectedness of the adverse event or reac-
tion (causality) will be assessed by the site investigator
and relayed to the chief investigator who, on behalf of
the sponsor (Newcastle upon Tyne Hospitals NHS
Foundation Trust), will notify the regulatory bodies, the
Medicines and the Healthcare Products Regulatory
Agency (MHRA) and the research ethics committee
(REC), within 7 days for fatal and life-threatening events
and 15 days for non-life-threatening events. All study
investigators will be notified.
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occur in this study, whether they are serious or not, will
be expected treatment-related toxicities due to the drugs
used in this study. A full summary of product character-
istics of Eltroxin have been published [18].
We do not anticipate adverse effects for the lower dose
of LT4. Although the current uniform serum TSH refer-
ence range of 0.4 to 4.0 is applied across all age groups,
in real practice a significant proportion of individuals do
have biochemical features of mild under-replacement,
which goes unrecognized until a blood test is performed.
If severe hypothyroidism develops (TSH >10 mU/L with
low FT4 levels), then symptoms including fatigue, weight
gain and poor memory may develop. We will assess the
clinical impact of thyroid function via hypothyroid-
specific symptom checklists, ThySRQ, and biochemically
(TSH and FT4 levels) at 12 and 24 weeks to detect individ-
uals who are unwittingly developing severe hypothyroidism.
We will adjust their LT4 dose accordingly. Participants will
also be provided with a helpline number in case they
experience any problems.
Statistical analysis
As this is a feasibility study, the analyses of the data col-
lected will be mainly descriptive, with 95% confidence inter-
vals reported where appropriate. As well as patient blinding
to treatment allocation, data analysis will also be blinded.
At baseline the distribution of all numerical variables will
be examined graphically and summarized by appropriate
measures of location and spread. Similarly, baseline categor-
ical variables will be tabulated and percentages reported.
Sample size calculation
No formal sample size calculation has been performed
for the RCT component of this feasibility study as the
primary outcome measures are concerned with the
recruitment to and randomization of the trial and the
acceptability of the trial in this population of patients.
As this is a trial with 6 months follow-up, any investiga-
tion of changes in key study parameters from baseline
to 6 months will only be exploratory. A sample size of
n = 50 will provide sufficient data [14] to estimate the
variability in the responses at baseline and assess the
feasibility of the trial.
SORTED B: qualitative study
Aim
The aim is to identify, describe and understand factors
associated with participation of elderly people in the
trial.
Objectives
The objectives are to explore the reasons for participa-
tion and non-participation in the RCT (SORTED A)amongst people aged 80 years and over with LT4-treated
primary hypothyroidism; to examine the decision-
making process of elderly people in choosing whether to
participate in the RCT; to explore aspects of health and
well-being with differing doses of LT4 replacement for
primary hypothyroid disease and to explore issues
around retaining elderly people in the RCT.Design and method
In-depth interviews with key informants, 8 to 10 people,
who have agreed to participate in the RCT (Group 1)
and 6 to 8 people who did not wish to participate in the
RCT (Group 2) will be conducted. Participants will be
approached sequentially.
To understand participants’ experiences of the trial (n = 8
to 10), we will focus on their experience of the medication
review (for example, the perceived impact on health and
well-being, any fears or concerns and compliance issues)
and their participation in the trial (for example, their
acceptability of trial processes, changes or improve-
ments they feel we could make and retention issues).
We will interview them at approximately 2 weeks after
randomization and up to 2 weeks after SORTED A visit
3 or trial termination whichever is sooner. These par-
ticipants will be recruited to Group 1.
To explore the reasons why patients declined to take
part in the RCT, we will focus on their understanding of
the trial processes (for example, the information they
were given, the encounter with the recruiter and their
ideas and/or concerns about randomization and con-
sent) and the intervention (willingness to have medica-
tion reviewed and/or changed, ideas and/or concerns
about the effect of a dosage change on their health).
These one-off interviews will take place within 2 weeks
of participants declining to take part in the trial so as to
minimize problems of information recall. These partici-
pants will be recruited to Group 2.
Participants will have the choice of being interviewed
alone or with their significant others, either in their own
homes or in an appropriate clinical setting.Participant recruitment and consent
Potential Group 1 participants will be approached by a
member of the central study team after they have provided
written informed consent for the RCT. They will be pro-
vided with a study invitation pack consisting of an invita-
tion letter, a participant information sheet and a consent
form for SORTED B Group 1. Following their agreement
to participate, the central study team will then contact po-
tential participants by telephone 7 (+/− 3) days later to
gauge the participants’ interest in taking part, to answer
any initial questions and to arrange a convenient place,
date and time for the interview.
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return reply slips to the central team to indicate that
they do not wish to participate in the RCT or when reply
slips are not received within the specified 4-week period.
This group is not identifiable to the central study team
and we will require the relevant NIHR Primary Care
Research Network research nurse, the general practice
staff or the secondary care clinician responsible for the
patients’ routine clinical care to approach this group.
Each potential participant will be sent a SORTED B
Group 2 invitation pack within 2 working days (after
checking living status) consisting of an invitation letter, a
participant information sheet, a consent form and a
stamped addressed envelope for returning the reply slip
to the central study team. For potential participants who
do not respond to the initial RCT (SORTED A) invitation,
the SORTED B Group 2 invitation pack will accompany
the reminder letter for the RCT, minimizing the number
of approaches to any particular patient.
For both groups, once initial agreement to participate
is given, an interview will be arranged by the central
study team either at the patient’s home or at Bensham
Hospital. The participant and a friend or relative (if
applicable) will be given an opportunity to ask questions.
Written informed consent will be obtained.
A pre-screening log will be held by the recruiting GP
surgery or hospital site, which will include the patient’s
name and address and the date of the invitation letter.
When reply slips of acceptance or refusal have been re-
ceived by the site study staff, the recruiting practice or hos-
pital site will be informed. If no reply is received, one
repeat invitation pack will be sent to potential participants.
Results and analysis
Interviews will be conducted by the research nurse. The in-
terviews will be semi-structured and the questions will be
open ended, neutral and sensitive to capture the experi-
ences of older people. All interviews will be audio-recorded
with the respondent’s written consent, transcribed (and
edited to ensure the anonymity of the respondent). The
transcripts will form the data for the formal analysis. We
will use QSR NVivo data collation and management soft-
ware to assist in the coding of the data. Analysis will be
conducted according to the standard procedures of rigor-
ous qualitative analysis (open and focused coding, constant
comparison, deviant case analysis and memoing) [20]. We
will also conduct a series of ‘data analysis clinics’ where the
research team will share and exchange interpretations of
emerging and key issues [21].
SORTED C: Retrospective cohort study
Aim
The aim is to collect the data required to inform a sam-
ple size calculation for SORTED II, the future full studywhere the primary outcome will be the 4-year all-cause
mortality and cardiovascular morbidity.Objectives
The objectives are to collect data to inform the design of
the future full study, SORTED II. In particular, they are to
estimate the distribution of the time-to-death variable for
treated hypothyroid patients aged 80 years and over with
4 years of follow-up and to describe a number of other
variables at study entry in 2008 for the cohort (time since
diagnosis of hypothyroidism, time since LT4 treatment
initiation, TSH level at diagnosis, FT4 level at diagnosis,
cause of death (if applicable), age, gender, smoking status,
body mass index, diabetes mellitus, hypertension and any
other significant co-morbidities).Design
This will be a retrospective cohort of 400 treated
hypothyroid patients aged 80 years or more registered in
2008 in primary care practices.Sample size
A total of 400 individuals who were 80 years or more in
2008 and were being treated for hypothyroidism will be
analyzed. This will provide a 95% CI for the mortality
rate in the population of interest with a width of at most
±5% to inform the power calculation for the full study.Sampling and participants
To identify patients for inclusion in the cohort study,
the general practice will perform a database search of
patient electronic records (Figure 1), which simultan-
eously identifies patients for SORTED A and C. Based
on the information collected in the feasibility work and
using an average practice list size of 7,000, we estimate
that we need to recruit 20 general practices to achieve a
sample size of at least 400 patients. In Northumberland,
Tyne and Wear there are approximately 300 general
practices of which 65 are GP research sites. The Primary
Care Research Network staff will identify 20 practices to
approach and will mail out the study literature. We do
not anticipate a problem recruiting general practices to
participate but if we cannot achieve our cohort of 400
patients from the first 20 general practices recruited, we
will approach further practices.Statistical analysis
As these data are being collected to inform the design of
a future full study, the analyses of the data collected will
be mainly descriptive, with 95% confidence intervals
reported where appropriate.
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A favorable ethics opinion has been received from Sun-
derland Research Ethics Committee (REC Reference: 12/
NE/0098). The conduct of this study will be in accord-
ance with the recommendations for physicians involved
in research on human subjects adopted by the 18th
World Medical Assembly, Helsinki 1964 and the princi-
ples of Good Clinical Practice [22], the MHRA [19] and
the Research Governance Framework for Health and
Social Care [23].
A data monitoring and ethics committee (DMEC) has
been convened to scrutinize the integrity of the trial
data and associated ethical issues. The DMEC members
are an independent chair, statistician and specialist
endocrinologist.
The trial steering committee (TSC) will provide overall
supervision for the trial on behalf of the trial sponsor,
Newcastle upon Tyne Hospitals NHS Foundation Trust,
and the trial funder, NIHR Research for Patient Benefit
(RfPB). The committee members are an independent
British Thyroid Foundation (BTF) member, the chief
investigator, three co-investigators, the trial statistician
and the trial manager.
The study will commence once all regulatory ap-
provals and Trust Research and Development approvals
via the NIHR Coordinated System for gaining NHS per-
missions (CSP) are in place for all participating sites.Discussion
As the UK population ages so does the prevalence of
thyroid disorders. Our study group argue that serum
thyroid hormone and TSH levels are not constant; with
free triiodothyronine (FT3) tending to decline and me-
dian TSH levels rising in advanced age in humans. Arti-
ficially imposing lower TSH reference ranges upon the
oldest old in our population may be exposing these indi-
viduals to increased all-cause mortality and cardiovascular
morbidity. This study prepares the way for a definitive trial,
SORTED II, to address the above hypothesis. SORTED A,
B and C will test the feasibility of the RCT procedures,
examine patient perspectives and describe the distribution
of a number of variables to help design the definitive trial
SORTED II.
Beyond SORTED II, if it is shown that older hypothyroid
patients require a lower dose of LT4 and that this strategy
improves morbidity and survival, then hundreds of thou-
sands of individuals worldwide would benefit. SORTED II
would provide compelling evidence to write definitive
guidelines to address the management of elderly pa-
tients currently diagnosed with hypothyroidism and sub-
clinical hypothyroidism. Furthermore, elderly individuals
with mildly raised TSH levels may not require treatment
at all, thus reclassifying them as ‘disease-free’.Trial status
The study received NHS ethics approval (REC Reference:
12/NE/0098) on 3 April 2012, NHS Trust governance ap-
provals on 25 July 2012 and recruitment commenced on
15 October 2012. Recruitment will proceed until 31 July
2013. Results will be submitted for publication in 2014.
Abbreviations
BTF: British thyroid foundation; CTX: Carboxy-terminal collagen crosslinks in
serum; DMEC: Data monitoring and ethics committee; EQ-5D: EuroQoL 5D;
FRAT: Falls risk assessment tool; FT3: Free triiodothyronine (thyroid hormone);
FT4: Free thyroxine; GP: General practitioner; HDL: High-density lipoprotein;
IMP: Investigational medicinal product; LT4: Levothyroxine; MHRA: Medicines
and healthcare products regulatory agency; NHANES III: National health and
nutritional estimates survey; NIHR: National institute for health research;
PIC: Participant identification center; PIS: Participant information sheet;
QoL: Quality of life; RCT: Randomized controlled trial; REC: Research ethics
committee; RfPB: Research for patient benefit; RVI: Royal victoria infirmary;
serum CTX: Serum collagen type-1 cross-linked C-telopeptide;
ThyDQoL: Underactive-thyroid-dependent quality of life questionnaire;
ThySRQ: Hypothyroid symptom checklist; TSC: Trial steering committee;
TSH: Thyroid stimulating hormone; TUG: Timed up and go test.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SR is the chief investigator, and conceived the study and led on protocol
development and grant acquisition. SW wrote this manuscript and approved
the final version for publication. SW, SP, VR, TR and LI are co-holders of the
grant and contributed to protocol development, study approvals and study
literature. SR and LI orchestrated drug supplies for the study. VR is the study
statistician. TR leads the qualitative aspects of the study. All authors have
commented upon drafts of the manuscript and have given final approval for
this version.
Acknowledgements
We would like to thank the following for their contribution: 1) The North
East Research Design Service for their advice in preparing the grant
application; 2) Dr Catherine Watson, trial manager, and Mrs Jennifer
Wilkinson, senior trial manager, Institute of Health & Society, Newcastle
University, Newcastle Clinical Trials Unit, for their help in preparing the trial
protocol documentation for submission to IRAS for governance and ethics
approvals and overall trial management; 3) Mrs Sally Black, MBE, for
assistance with proofreading and editing of this manuscript; 4) the NIHR
Clinical Research Network, in particular the Northumberland, Tyne and Wear
Comprehensive Local Research Network, the Primary Care Research Network
Northern and Yorkshire, and the NIHR primary care delivery staff of NHS
North of Tyne for their assistance in identifying sites for study delivery; 5) the
pharmacy team at Newcastle upon Tyne Hospitals NHS Foundation Trust,
who facilitated drug procurement, over-encapsulation and advised and
assisted with all other pharmacy arrangements; 6) TSC members: Dr
Catherine Watson (trial manager), Mrs Janis Hickey (BTF member) as well as
SR, SW, SP, VR and LI; 7) DMEC members: Ramzi Ajian (independent chair),
Petros Perros (independent local expert), Dr Barbara Gregson (independent
statistician).
This project is funded by the NIHR RfPB (http://www.ccf.nihr.ac.uk/RfPB/
about/Pages/FundedProjects1.aspx, reference PB-PG-0610 22139).
The views expressed in this paper are those of the authors and not
necessarily those of the NHS, the NIHR or the Department of Health.
Author details
1Institute of Health & Society, Newcastle University, Newcastle upon Tyne
NE2 4AX. 2Institute of Genetic Medicine, International Centre for Life, Central
Parkway, Newcastle upon Tyne NE1 3BZ, UK. 3Department of Endocrinology,
Queen Elizabeth Hospital, Gateshead NE9 6SX, UK.
Received: 17 September 2012 Accepted: 28 February 2013
Published: 22 March 2013
Wilkes et al. Trials 2013, 14:83 Page 12 of 12
http://www.trialsjournal.com/content/14/1/83References
1. UK National Statistics. [http://www.statistics.gov.uk/hub/population/
population-change/population-projections/index.html]
2. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer
CA, et al: Serum TSH, T(4), and thyroid antibodies in the United States
population (1988 to 1994): National Health and Nutrition Examination
Survey (NHANES III). J Clin Endocrinol Metab 2002, 87(2):489.
3. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al: The
spectrum of thyroid disease in a community: the Whickham survey.
Clin Endocrinol 1977, 7(6):481–493.
4. Surks MI, Hollowell JG: Age-specific distribution of serum thyrotropin and
antithyroid antibodies in the US population: implications for the
prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 2007,
92(12):4575–4582.
5. Parle J, Roberts L, Wilson S, Pattison H, Roalfe A, Haque MS, et al: A
randomized controlled trial of the effect of thyroxine replacement on
cognitive function in community-living elderly subjects with subclinical
hypothyroidism: the Birmingham Elderly Thyroid study. J Clin Endocrinol
Metab 2010, 95(8):3623–3632.
6. Biondi B, Cooper DS: The clinical significance of subclinical thyroid
dysfunction. Endocr Rev 2008, 29(1):76–131.
7. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp
RG: Thyroid status, disability and cognitive function, and survival in old
age. JAMA 2004, 292(21):2591–2599.
8. Simonsick EM, Newman AB, Ferrucci L, Satterfield S, Harris TB, Rodondi N, et al:
Subclinical hypothyroidism and functional mobility in older adults. Arch
Intern Med 2009, 169(21):2011–2017.
9. Bauer DC, Rodondi N, Stone KL, Hillier TA, Study of Osteoporotic Fractures
Research Group: Universities of California (San Francisco), Kaiser Permanente
Center for Health Research P: Thyroid hormone use, hyperthyroidism and
mortality in older women. Am J Med 2007, 120(4):343–349.
10. Razvi S, Shakoor A, Vanderpump M, Weaver JU, Pearce SH: The influence of
age on the relationship between subclinical hypothyroidism and ischemic
heart disease: a metaanalysis. J Clin Endocrinol Metab 2008, 93(8):2998–3007.
11. Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J, et al: Meta-
analysis: subclinical thyroid dysfunction and the risk for coronary heart
disease and mortality. Ann Intern Med 2008, 148(11):832–845.
12. Cooper DS: Thyroid disease in the oldest old: the exception to the rule.
JAMA 2004, 292(21):2651–2654.
13. Allahabadia A, Razvi S, Abraham P, Franklyn J: Diagnosis and treatment of
primary hypothyroidism. BMJ 2009, 338:b725.
14. Lancaster GA, Dodd S, Williamson PR: Design and analysis of pilot studies:
recommendations for good practice. J Eval Clin Pract 2004, 10(2):307–312.
15. The EQ-5D health questionnaire. [http://www.euroqol.org/eq-5d.html]
16. McMillan C, Bradley C, Razvi S, Weaver J: Evaluation of new measures of
the impact of hypothyroidism on quality of life and symptoms: the
ThyDQoL and ThySRQ. Value Health 2008, 11(2):285–294.
17. Stapleton C, Hough P, Bull K, Hill K, Greenwood K, Oldmeadow L: A 4-item
falls-risk screening tool for sub-acute and residential care: The first step
in falls prevention. Australas J Ageing 2009, 28(3):139–143.
18. EMC Mercury Pharmaceuticals. [http://www.medicines.org.uk/EMC/
medicine/27214/PIL/Eltroxin+50+and+100+micrograms+Tablets/]
19. Medicines for Human use in Clinical Trials. [http://www.uk-legislation.
hmso.gov.uk/si/si2004/20041031.htm]
20. Strauss ACJ: Basics of Qualitative Research. Grounded Theory Procedures and
Techniques. Sage: Newbury Park; 1990.
21. Denzin NK, Lincoln YS: Handbook of Qualitative Research. London: Sage
Publications; 1994.
22. ICH Harmonised Tripartite Guideline for Good Clinical Practice.
[http://www.ich.org]
23. Department of Health: Research Governance Framework for Health and Social
Care. 2nd edition. 2005. http://www.dh.gov.uk/en/Publicationsandstatistics/
Publications/PublicationsPolicyAndGuidance/DH_4108962.
doi:10.1186/1745-6215-14-83
Cite this article as: Wilkes et al.: Study of Optimal Replacement of
Thyroxine in the ElDerly (SORTED): protocol for a mixed methods
feasibility study to assess the clinical utility of lower dose thyroxine in
elderly hypothyroid patients: study protocol for a randomized
controlled trial. Trials 2013 14:83.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
